What You need to Know About Legend Biotech (LEGN)

Shares of Legend Biotech surged 11.5% today, and are now trading at a price of $51.95. In contrast, the S&P 500 index saw a -0.1% change. Today's trading volume is 471,612 compared to the stock's average volume of 677,624.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Based in Somerset, United States the company has 1,071 full time employees and a market cap of $8,696,586,240.

The company is now trading -24.59% away from its average analyst target price of $68.89 per share. The 9 analysts following the stock have set target prices ranging from $53 to $79, and on average give Legend Biotech a rating of buy.

Over the last year, LEGN shares have gone up 2.1%, which represents a difference of 19.5% when compared to the S&P 500. The stock's 52 week high is $57.67 per share whereas its 52 week low is $30.755.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.